{"componentChunkName":"component---node-modules-gatsby-theme-buzzing-src-gatsby-theme-blog-core-templates-post-query-js","path":"/reddit/r/stocks/comments/qh5e1e/teladoc_health_reports_thirdquarter_2021_results/","result":{"data":{"site":{"siteMetadata":{"title":"国外股市热门","author":"Buzzing.cc","description":"用中文浏览国外股票社区里的热门讨论","keywords":["buzzing","美股","股票","股市"],"siteUrl":"https://stocks.buzzing.cc","telegram":"@stocks_top","iconUrl":"https://stocks.buzzing.cc/avatar.png","defaultSocialImageUrl":null,"social":[{"name":"Reddit Stocks","url":"https://www.reddit.com/r/stocks","external":true},{"name":"Reddit Investing","url":"https://www.reddit.com/r/investing","external":true},{"name":"Charlie Bilello's twitter","url":"https://twitter.com/charliebilello","external":true},{"name":"Buzzing","url":"https://www.buzzing.cc/","external":true}],"menuLinks":[{"name":"每周精选","url":"/issues","external":null}],"disqus":null,"utterances":null,"localize":[{"title":"Buzzing on Stocks","description":"See popular discussions in foreign stock communities in your native language","keywords":["buzzing","stocks","U.S. stocks"],"locale":"en","social":{"name":null,"url":null,"external":null},"menuLinks":[{"name":"Weekly Selection","url":"/en/issues","external":null}]},{"title":"國外股市熱門","description":"用中文瀏覽國外股票社區裡的熱門討論","keywords":["buzzing","美股","股票","股市"],"locale":"zh-Hant","social":null,"menuLinks":[{"name":"每週精選","url":"/zh-Hant/issues","external":null}]},{"title":"米国株式市場人気の話し合います","description":"人気の米国株式市場の話し合いまを日本語で閲覧","keywords":["buzzing","米国株式市場"],"locale":"ja","social":null,"menuLinks":[]}]}},"blogPost":{"id":"RedditPost-qh5e1e","excerpt":" * Third quarter revenue grows 81% year-over-year to $522 million, updating 2021\n   revenue outlook to $2,015 million to $2,025 million.\n\n * Total third quarter visits top 3.9 million – 37% higher than Q3 2020.\n\n * Significant new agreements with CVS Health and Centene to provide Teladoc\n   Health’s…","body":"<!-- SC_OFF --><div class=\"md\"><ul>\n<li><p><em>Third quarter revenue grows 81% year-over-year to $522 million, updating 2021 revenue outlook to $2,015 million to $2,025 million.</em>  </p></li>\n<li><p><em>Total third quarter visits top 3.9 million – 37% higher than Q3 2020.</em>  </p></li>\n<li><p><em>Significant new agreements with CVS Health and Centene to provide Teladoc Health’s Primary360 to deliver greater care access and health engagement.</em>  </p></li>\n<li><p><em>Teladoc Health ranked 1st in consumer satisfaction by J.D. Power 2021 U.S. Telehealth Satisfaction Study.</em></p></li>\n</ul>\n\n<p>PURCHASE, NY, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the quarter ended September 30, 2021.  </p>\n\n<p>“Our strong performance in the third quarter reflects our continued success in leading the transformation of healthcare delivery and expanding access for all,” said Jason Gorevic, chief executive officer at Teladoc Health. “By leveraging our unique combination of data, analytics, technology and dedicated healthcare professionals, we are driving growth across our business. The third quarter was notable in expanding relationships with a number of leading national health plans with the successful launch of our Primary360 offering which reimagines the primary care model and delivers increased access and engagement to members.”</p>\n\n<p>“As we look ahead to the rest of 2021 and into 2022, we are confident in our ability to innovate, anticipate and solve for the evolving whole-person health needs of consumers and healthcare professionals globally,&quot; Gorevic added.</p>\n\n<p>Platform-Enabled Sessions are a unique instance in which our licensed software platform has facilitated a virtual voice or video encounter between a care provider and our client’s patient, or between care providers. We believe platform-enabled sessions are an indicator of the value our clients derive from the platform they license from us in order to facilitate virtual care.</p>\n\n<ul>\n<li><p><strong>Net loss</strong> was $(84.3) million for the third quarter of 2021 compared to $(35.9) million for the third quarter of 2020. Net loss was $(417.8) million for the first nine months of 2021 compared to $(91.2) million for the first nine months of 2020. The third quarter and first nine months of 2021 include stock-based compensation expense of $71.7 million and $241.0 million, respectively, representing increases of $50.8 million and $179.8 million, respectively, from the third quarter and first nine months of 2020, substantially reflecting higher expense associated with Livongo stock awards that continue to vest after the merger. Net loss also includes amortization of acquired intangibles of $45.1 million and $133.8 million, respectively, for the third quarter and first nine months of 2021, representing increases of $35.0 million and $109.2 million, respectively, from the third quarter and first nine months of 2020, substantially reflecting higher amortization of acquired intangible assets from the Livongo and InTouch Health acquisitions. Net loss also includes loss on extinguishment of debt of $0.8 million and $43.7 million, respectively, for the third quarter and first nine months of 2021, a decrease of $0.4 million and an increase of $34.7 million, respectively, from the third quarter and first nine months of 2020, primarily reflecting the exchange of convertible senior notes in the first nine months of 2021. Net loss also includes non-cash income tax expense of $3.6 million and $93.9 million, respectively, for the third quarter and first nine months of 2021, substantially reflecting the recording of a valuation allowance on stock compensation benefits associated with the Livongo merger recorded in the first quarter of 2021.  </p></li>\n<li><p><strong>Net loss per basic and diluted share</strong> was $(0.53) for the third quarter of 2021 compared to $(0.43) for the third quarter of 2020. Net loss per basic and diluted share was $(2.68) and $(1.17) for the first nine months of 2021 and 2020, respectively. Net loss per basic and diluted share includes stock-based compensation expense of $0.45 per share and $0.25 per share for the third quarter of 2021 and 2020, respectively, and $1.55 per share and $0.79 per share for the first nine months of 2021 and 2020, respectively. Net loss per basic and diluted share also includes amortization of acquired intangible assets of $0.28 per share and $0.12 per share for the third quarter of 2021 and 2020, respectively, and $0.86 per share and $0.32 per share for the first nine months of 2021 and 2020, respectively. Net loss per basic and diluted share also includes loss on extinguishment of debt of $0.01 per share for the third quarter of both 2021 and 2020, and $0.28 per share and $0.12 per share for the first nine months of 2021 and 2020, respectively. In addition, net loss per basic and diluted share includes the non-cash income tax charge (benefit) referred to above of $0.02 per share and $(0.03) per share for the third quarter of 2021 and 2020, respectively, and $0.60 per share for the first nine months of 2021 as compared to a benefit of $(0.07) per share in the first nine months of 2020. The number of weighted-average shares outstanding was 159.4 million and 155.9 million for the third quarter and first nine months of 2021, respectively, up from 83.6 million and 77.8 million for the third quarter and first nine months of 2020, substantially reflecting the impact of the Livongo and InTouch Health acquisitions.  </p></li>\n<li><p><strong>GAAP Gross margin,</strong> which includes depreciation and amortization, was 67.1 percent for the third quarter of 2021 and 63.3 percent for the third quarter of 2020. For the first nine months of 2021 and 2020, GAAP Gross margin was 67.3 percent and 61.7 percent, respectively.  </p></li>\n<li><p><strong>Adjusted Gross margin</strong> was 67.6 percent for the third quarter of 2021 compared to 63.7 percent for the third quarter of 2020. For the first nine months of 2021 and 2020, Adjusted Gross margin was 67.9 percent and 62.3 percent, respectively.  </p></li>\n<li><p><strong>EBITDA</strong> was a loss of $(8.7) million for the third quarter of 2021 compared to a loss $(6.8) million for the third quarter of 2020. EBITDA was a loss of $(72.3) million and $(15.4) million, respectively, for the first nine months of 2021 and 2020. EBITDA includes stock-based compensation expense of $71.7 million and $241.0 million for the third quarter and first nine months of 2021, respectively, representing increases of $50.8 million and $179.8 million from the third quarter and first nine months of 2020, respectively, substantially reflecting higher expense associated with Livongo stock awards that continue to vest after the merger. EBITDA also includes acquisition, integration and transformation costs of $4.3 million and $22.1 million for the third quarter and first nine months of 2021, respectively, representing decreases of $21.1 million and $8.6 million from the third quarter and first nine months of 2020, respectively.  </p></li>\n<li><p><strong>Adjusted EBITDA</strong> was $67.4 million for the third quarter of 2021 compared to $39.5 million for the third quarter of 2020. Adjusted EBITDA was $190.8 million for the first nine months of 2021 compared to $76.5 million for the first nine months of 2020.</p></li>\n</ul>\n\n<p>A reconciliation of generally accepted accounting principles (“GAAP”) in the United States to non-GAAP results has been provided in this press release in the accompanying tables. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures.”</p>\n\n<p><strong>Financial Outlook</strong><br/>\nTeladoc Health provides guidance based on current market conditions and expectations. Given the uncertainty of the expected path of the COVID-19 pandemic as well as the broader economic impact, our updated guidance is based on what we know today. As this is an evolving situation, circumstances are likely to change, but we believe our guidance ranges provide a reasonable baseline for 2021 financial performance.</p>\n\n<p><strong>For the fourth-quarter 2021, we expect:</strong></p>\n\n<ul>\n<li>Total revenue to be in the range of $536 million to $546 million.</li>\n<li>EBITDA to be in the range of $(8) million to $(3) million.</li>\n<li>Adjusted EBITDA to be in the range of $69 million to $74 million.</li>\n<li>Net loss per share, based on 160 million weighted average shares outstanding, to be between $(0.73) and $(0.53).</li>\n<li>Total U.S. paid membership to be in the range of 52.5 million to 53.5 million members and visit fee only access to be available to approximately 23 million to 24 million individuals.</li>\n<li>Total visits to be between 3.9 million and 4.1 million.</li>\n</ul>\n\n<p><strong>For the full-year 2021, we expect:</strong></p>\n\n<ul>\n<li>Total revenue to be in the range of $2,015 million to $2,025 million.</li>\n<li>EBITDA to be in the range of $(80) million to $(75) million.</li>\n<li>Adjusted EBITDA to be in the range of $260 million to $265 million, including an estimated $20 million in lower expenses primarily related to Livongo devices as a result of the merger.</li>\n<li>Net loss per share, based on 157 million weighted average shares outstanding, to be between $(3.40) and $(3.20).</li>\n<li>Total U.S. paid membership to be in the range of 52.5 million to 53.5 million members and visit fee only access to be available to approximately 23 million to 24 million individuals.</li>\n<li>Total visits to be between 14.5 million and 14.7 million.</li>\n</ul>\n\n<p><a href=\"https://ir.teladochealth.com/news-and-events/investor-news/press-release-details/2021/Teladoc-Health-Reports-Third-Quarter-2021-Results/default.aspx\">https://ir.teladochealth.com/news-and-events/investor-news/press-release-details/2021/Teladoc-Health-Reports-Third-Quarter-2021-Results/default.aspx</a></p>\n</div><!-- SC_ON -->","slug":"/reddit/r/stocks/comments/qh5e1e/teladoc_health_reports_thirdquarter_2021_results/","title":"Teladoc Health Reports Third-Quarter 2021 Results","tags":["stocks","reddit"],"date":"October 28, 2021","dateISO":"2021-10-28T03:34:17.000Z","datetime":"2021-10-28 03:34","image":null,"imageAlt":null,"socialImage":null,"__typename":"SocialMediaPost","thirdPartyId":"qh5e1e","provider":"Reddit","url":"https://www.reddit.com/r/stocks/comments/qh5e1e/teladoc_health_reports_thirdquarter_2021_results/","originalUrl":"https://www.reddit.com/r/stocks/comments/qh5e1e/teladoc_health_reports_thirdquarter_2021_results/","imageRemote":null,"video":null,"channel":"stocks","channelUrl":"https://www.reddit.com/r/stocks","author":"TaxShield","authorUrl":"https://www.reddit.com/user/TaxShield","authorImage":null,"authorImageRemote":null,"authorSlug":"TaxShield","score":62,"views":null,"sharedCount":null,"likeCount":null,"sharedContent":null,"parent":{"localize":[{"title":"Teladoc Health社、2021年第3四半期の業績を発表","the_new_excerpt":" * 第3四半期の売上高は前年同期比81％増の5億2,200万ドル、2021年の売上高見通しを20億1,500万ドルから20億ドルに更新。\n   2021年の収益見通しを2,015百万ドルから2,025百万ドルに更新。\n\n * 第3四半期の総訪問者数は390万人を超え、2020年第3四半期と比較して37％増。\n\n * Teladocを提供するCVS HealthおよびCenteneとの重要な新規契約。\n   Health社の...","locale":"ja"},{"title":"Teladoc Health公布2021年第三季度业绩","the_new_excerpt":" * 第三季度收入同比增长81%，达到5.22亿美元，更新2021年\n   收入展望为20.15亿美元至20.25亿美元。\n\n * 第三季度总访问量达到390万人次--比2020年第三季度高出37%。\n\n * 与CVS Health和Centene达成重要的新协议，提供Teladoc\n   健康公司的...","locale":"zh"},{"title":"Teladoc Health公佈2021年第三季度業績","the_new_excerpt":" * 第三季度收入同比增長81%，達到5.22億美元，更新2021年\n   收入展望爲20.15億美元至20.25億美元。\n\n * 第三季度總訪問量達到390萬人次--比2020年第三季度高出37%。\n\n * 與CVS Health和Centene達成重要的新協議，提供Teladoc\n   健康公司的...","locale":"zh-Hant"}]}},"previous":{"id":"RedditPost-qgz9em","excerpt":"Forgive the simplicity of this post, am dumb: I only buy shares, never bought\ncalls or puts and don’t know how. But it seems that in the longterm, SPY always\ngoes up.\n\nWhy doesn’t everyone just buy as many calls as they can for years out? Is there\na maximum amount of time length you can have for a…","slug":"/reddit/r/stocks/comments/qgz9em/why_doesnt_everyone_just_do_longterm_spy_calls/","title":"Why doesn’t everyone just do longterm SPY calls?","date":"October 28, 2021","__typename":"SocialMediaPost","provider":"Reddit","parent":{"localize":[{"title":"なぜみんなSPYの長期コールをやらないの？","the_new_excerpt":"この記事のシンプルさを許してください、私は馬鹿です：私は株式を購入するだけで、購入したことはありません。\nコールやプットを買ったことがなく、やり方も知りません。しかし、長期的にはSPYは常に上昇すると思われます。\n上がるように思えます。\n\nなぜ誰もが何年も先のことを考えてできるだけ多くのコールを買わないのでしょうか？それは\nあなたが持つことができる最大の時間の長さがあります...","locale":"ja"},{"title":"为什么大家不直接做长期的SPY看涨期权？","the_new_excerpt":"请原谅这篇文章的简单性，我是个哑巴：我只买股票，从来没有买过看涨或看跌期权，也不知道该怎么办。\n看涨或看跌期权，也不知道怎么买。但从长期来看，SPY似乎总是\n上升。\n\n为什么每个人都不买尽可能多的看涨期权，而是买好几年的？是否有\n你可以有一个最大的时间长度。","locale":"zh"},{"title":"爲什麼大家不直接做長期的SPY看漲期權？","the_new_excerpt":"請原諒這篇文章的簡單性，我是個啞巴：我只買股票，從來沒有買過看漲或看跌期權，也不知道該怎麼辦。\n看漲或看跌期權，也不知道怎麼買。但從長期來看，SPY似乎總是\n上升。\n\n爲什麼每個人都不買儘可能多的看漲期權，而是買好幾年的？是否有\n你可以有一個最大的時間長度。","locale":"zh-Hant"}]}},"next":{"id":"TweetPost-1453536452999008269","excerpt":"","slug":"/tweet/1453536452999008269","title":"https://t.co/GcTXW6kFyq","__typename":"SocialMediaPost","date":"October 28, 2021","provider":"Twitter","parent":{"localize":[{"locale":"ja","full_text":"https://t.co/GcTXW6kFyq","quoted_status_full_text":null,"retweeted_status_full_text":null},{"locale":"zh","full_text":"https://t.co/GcTXW6kFyq","quoted_status_full_text":null,"retweeted_status_full_text":null},{"locale":"zh-Hant","full_text":"https://t.co/GcTXW6kFyq","quoted_status_full_text":null,"retweeted_status_full_text":null}]}}},"pageContext":{"basePath":"/","pageType":"detail","id":"RedditPost-qh5e1e","previousId":"RedditPost-qgz9em","nextId":"TweetPost-1453536452999008269","maxWidth":1024,"siteMetadata":null,"locale":"zh","hrefLang":"zh-Hans","originalPath":"/reddit/r/stocks/comments/qh5e1e/teladoc_health_reports_thirdquarter_2021_results/","dateFormat":"YYYY-MM-DD"}},"staticQueryHashes":["1239077767","2744905544","3280999885"]}